Navigation Links
NovoCure Ltd. announces closing of financing round
Date:9/28/2009

September 28, 2009 NovoCure, Ltd., a privately held medical device company focused on developing the Novo-TTF device, a non-invasive portable medical device for the treatment of cancer, announced the completion of a new funding round today. Key investors in this round included Pfizer Inc, Johnson & Johnson Development Corporation and Index Ventures. "We are very pleased that Pfizer, Johnson & Johnson Development Corporation and Index have taken an interest in the work we're doing with the Novo-TTF device," said William Doyle, Chairman of the Board of NovoCure. "The proceeds from their investment will be used to fund NovoCure's newly-diagnosed GBM pivotal clinical trial."

"The NovoCure TTF therapy is a completely novel approach to fighting cancer," said Bill Burkoth, Director of Pfizer Ventures. "Pilot clinical trials suggest that TTF therapy plus chemotherapy has the potential to significantly improve patient survival.

This investment aligns with Pfizer's goal to help oncology patients live longer, healthier lives."

The Novo-TTF device is a unique cancer treatment that uses specially tuned, low intensity electrical fields (Tumor Treating Fields or TTFields) to disrupt cell division. Rapidly dividing cancerous cells are affected by the TTFields , causing them to either break apart or not divide properly, while healthy, non-dividing cells are not affected, yielding a targeted treatment with minimal side effects. The fields are applied to the tumor region using non-invasive, insulated electrodes placed on a patient's skin. The electrodes, which look like bandages, are attached by wires to a battery operated, portable device that generates the fields.

INITIATION OF CLINICAL TRIAL FOR NEWLY DIAGNOSED GBM

The Novo-TTF device has been tested in more than 175 patients with various types of cancers including recurrent and newly-diagnosed glioblastoma multiforme (GBM), breast cancer and lung cancer.

NovoCure rece
'/>"/>

Contact: Jennifer Paganelli Schwartz
jennifer.schwartz@edelman.com
212-642-7774
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NovoCure presents results from breast cancer pilot study
2. RCRC Independent Review Board Announces DHHS Research Oversight
3. change:healthcare Announces Twitter Application that brings Healthcare Information and Costs to Consumers' Fingertips
4. QRxPharma Announces Strategic Alliance with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
5. I-Therapeutix, Inc. Announces Company Name Change
6. President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
8. US Farms, Inc. Announces Broker Network Agreement With Sunshine Specialties for Aloe365 Products
9. ReBuilder Medical Technologies, Inc. Announces Medicare Billing Ability for its ReBuilder Product
10. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
11. Strategic Information Group Announces QAD Enterprise Validation Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... Oregon (PRWEB) February 28, 2015 The ... Oregon, is offering a new special. Throughout all ... relines. , This service can ... sleep problems and pain. Patients may notice certain symptoms ... need relining. These symptoms include: , 1.    Pain, clicking, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... to discuss federal testosterone lawsuits that have been filed ... scheduled for the second week in March, the Firm ... the Court’s website, parties involved in the federal litigation ... to address matters related to prescription therapy treatments designed ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... the disease, , , WEDNESDAY, April 15 (HealthDay News) ... the tracking of changes in cancer cells, according ... Medicine. , The technology uses specially designed dye-containing ... or on a single cell. , Current single-flow ...
... RequirementsTAMPA, Fla., April 15 Sage Software Healthcare, ... today announced that The Certification Commission for Healthcare ... Intergy EHR, as a CCHIT Certified(R) ... certified for Child Health and Cardiovascular Medicine, and ...
... Emory University, developed a test in nonhuman primates that ... cognitive impairment (MCI) in humans. The researchers hope the ... of Alzheimer,s disease. The test, which is featured in ... of Alzheimer,s Disease and Other Dementias , is helping ...
... Dinotefuran and Pyriproxyfen Combination Delivers Safe and Effective Control ... April 15 Summit VetPharm announces the introduction of ... flea control product containing dinotefuran and pyriproxyfen in combination ... that protects your dog from all stages of fleas ...
... Voice-Assisted Care and Pathway Health Services Bring Better ... Facilities in Long-Term CarePITTSBURGH, April 15 Vocollect ... a nationally recognized consulting and management company for ... home care markets, announce an agreement whereby Pathway ...
... April 15 ... landmark in the employee phase of the "Our House is ... and Kemmons Wilson Family Center for Good Grief as they ... began in November of 2008, with 60 employee volunteers across ...
Cached Medicine News:Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Yerkes researchers use eye tracking to detect mild dementia in humans 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 3Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 4Health News:Pathway Health Services and Vocollect Healthcare Systems Announce Strategic Partnership 2Health News:Baptist Colleagues Raise $1 Million for Baptist Trinity Hospice House and Kemmons Wilson Family Center for Good Grief 2
(Date:2/27/2015)... 2015 An aggressive campaign to reduce the ... of infection with a dangerous drug-resistant bacteria at The ... difficile, or C.diff, is a bacterium that can cause ... colon. A recent article in the New England Journal ... the United States " asserts that ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
(Date:2/27/2015)... Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the fourth quarter and full ... was a transformative year for PTC. We are now ... developing RNA-targeted therapies in the rare disease space," stated ... Inc. "We are proud to bring the first treatment ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... Congress on Obesity (ECO) in Istanbul, Turkey.  ECO is the ... of Obesity (EASO). ECO is regularly attended by more than ... be the most important annual scientific event on obesity in ...
... 2011 MicroVention-Terumo, Inc., a leader in developing, ... the final 18-month follow-up data in a landmark ... Packing Study (HELPS) published in The Lancet ... treating cerebral aneurysms reduced recurrence and retreatment rates ...
Cached Medicine Technology:Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 2Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 3Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 4Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity 5Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 2Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 3Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumo's HydroCoil® Embolic System for Treatment of Cerebral Aneurysms 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: